May 3, 2021
MediSieve Expands its Team and Laboratory Space
MediSieve’s continues accelerating the development of it research programmes with the expansion of the lab space and the recruitment of two interns.
LONDON – May 03, 2021 – MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, continues accelerating the development of it research programmes with the expansion of the laboratory space, as well as the recruitment of two interns.
Having pivoted their technology to treat hyperinflammation in COVID-19, the MediSieve team has moved into their own space at the White City Incubator. The team worked continuously in their shared lab throughout the pandemic and were able to use space in the Incubator flexibly when needed. With the new COVID-19 programme firmly at the centre of their work they have now decided to move into their own lab to accelerate the safety studies and move towards the first in-man trials of this application.
“We are very happy to be in our own lab space,” says Dr Cristina Blanco-Andujar, Chief Technology Officer of MediSieve. “It has improved our workflow hugely as we now have dedicated areas for different activities so everything can be very controlled. In addition, this new space represents our development over the last year and makes our progression feel really tangible. The team is very excited about the future.”
Recently, the company added two new interns to its team in order to accelerate the development of its pivotal IL-6 programme. Ksenia Ellum will be contributing to product development by working closely with other team members to create new insights through data analysis and processing. She will help drive efficient innovation by contributing to a deeper understanding of the product. Molly Abraham will be joining the team this summer to investigate an improved method of bead separation using magnetic simulation software to guide the design of a prototype product. Molly will then 3D print and assemble the new prototype and arrange experiments with the Lab Team to evaluate the performance.
“This is an exciting time for MediSieve, and it's wonderful to welcome our new employees. I am confident that the new team members will thrive in our collaborative environment and help accelerate MediSieve's solution, which can benefit patients all over the world”, said Dr George Frodsham, Founder and CEO of MediSieve.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: